-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
      name:  <unnamed>
       log:  /disk/homedirs/nber/bergerb/cortellis_projects/clinical_trials/reports/report_10-20-17/regs/regression_output_10-20-17.log
  log type:  text
 opened on:  29 Oct 2017, 16:48:06

. 
. 
. cap drop any_public*

. gen any_public = sponsor_public == 1 | collaborator_public == 1

. gen any_public_max = sponsor_public_max == 1 | collaborator_public_max == 1

. label variable any_public "Public firm (lower bound)"

. label variable any_public_max "Public firm (upper bound)"

. 
. * ------------------------------*
. * Main PPM regressions (Table 7)
. * ------------------------------*
. ppm_regs, ppm(g_ppm) estimator(regress) quietly 
Dependent variable: g_ppm

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       reg1f   &       reg1g   &       reg1h   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year    &      0.0038*  &      0.0038*  &      0.0038*  &      0.0038*  &      0.0051   &      0.0051*  &      0.0050   &      0.0051*  \\
                    &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0024)   &    (0.0024)   &    (0.0024)   &    (0.0024)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&      0.0099   &      0.0102   &      0.0099   &      0.0102   &      0.0126   &      0.0129   &      0.0130   &    
>   0.0133   \\
                    &    (0.0095)   &    (0.0096)   &    (0.0094)   &    (0.0094)   &    (0.0110)   &    (0.0110)   &    (0.0107)   &    (0.0108)   \\
Phase 3 Clinical    &      0.0170   &      0.0168   &      0.0171   &      0.0169   &      0.0194   &      0.0191   &      0.0198   &      0.0196   \\
                    &    (0.0146)   &    (0.0146)   &    (0.0144)   &    (0.0143)   &    (0.0161)   &    (0.0160)   &    (0.0159)   &    (0.0158)   \\
Trial site in US=1  &      0.0126***&      0.0118***&      0.0121** &      0.0112** &      0.0131***&      0.0122***&      0.0087*  &      0.0078*  \\
                    &    (0.0021)   &    (0.0022)   &    (0.0033)   &    (0.0031)   &    (0.0026)   &    (0.0028)   &    (0.0035)   &    (0.0035)   \\
Drug indication for neoplasm=1&      0.1373***&      0.1375***&      0.1367***&      0.1368***&      0.1504***&      0.1504***&      0.1447***&      0.1448***\\
                    &    (0.0148)   &    (0.0148)   &    (0.0121)   &    (0.0121)   &    (0.0186)   &    (0.0186)   &    (0.0134)   &    (0.0134)   \\
NIH funding         &      0.0110   &      0.0125*  &      0.0109   &      0.0123*  &      0.0096   &      0.0111   &      0.0077   &      0.0092   \\
                    &    (0.0062)   &    (0.0058)   &    (0.0058)   &    (0.0054)   &    (0.0076)   &    (0.0070)   &    (0.0063)   &    (0.0057)   \\
Biomarker type: genomic=1&      0.2441*  &      0.2441*  &      0.2441*  &      0.2441*  &      0.2417*  &      0.2417*  &      0.2412*  &      0.2413*  \\
                    &    (0.1107)   &    (0.1106)   &    (0.1108)   &    (0.1108)   &    (0.1134)   &    (0.1133)   &    (0.1137)   &    (0.1136)   \\
Public firm (lower bound)&      0.0109*  &               &      0.0109*  &               &      0.0134*  &               &      0.0133*  &               \\
                    &    (0.0042)   &               &    (0.0042)   &               &    (0.0058)   &               &    (0.0059)   &               \\
Public firm (upper bound)&               &      0.0124*  &               &      0.0124*  &               &      0.0141*  &               &      0.0140*  \\
                    &               &    (0.0047)   &               &    (0.0046)   &               &    (0.0060)   &               &    (0.0060)   \\
Trial site in US=1 $\times$ Drug indication for neoplasm=1&               &               &      0.0014   &      0.0015   &               &               &      0.0132
>    &      0.0130   \\
                    &               &               &    (0.0075)   &    (0.0075)   &               &               &    (0.0130)   &    (0.0130)   \\
Constant            &     -7.7453*  &     -7.7695*  &     -7.7483*  &     -7.7726*  &    -10.2273   &    -10.3223*  &    -10.2075   &    -10.3018*  \\
                    &    (2.8311)   &    (2.7854)   &    (2.8173)   &    (2.7716)   &    (4.8688)   &    (4.8559)   &    (4.8819)   &    (4.8700)   \\
N                   &      107430   &      107430   &      107430   &      107430   &       91371   &       91371   &       91371   &       91371   \\
r2                  &       0.272   &       0.272   &       0.272   &       0.272   &       0.280   &       0.280   &       0.280   &       0.280   \\
* p<0.05, ** p<0.01, *** p<0.001

. ppm_regs, ppm(r_ppm) estimator(regress) quietly
Dependent variable: r_ppm

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       reg1f   &       reg1g   &       reg1h   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year    &      0.0034*  &      0.0034*  &      0.0034*  &      0.0034*  &      0.0044   &      0.0045   &      0.0044   &      0.0045   \\
                    &    (0.0014)   &    (0.0013)   &    (0.0014)   &    (0.0013)   &    (0.0023)   &    (0.0023)   &    (0.0023)   &    (0.0023)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&      0.0130   &      0.0133   &      0.0131   &      0.0134   &      0.0156   &      0.0159   &      0.0161   &    
>   0.0164   \\
                    &    (0.0101)   &    (0.0102)   &    (0.0100)   &    (0.0100)   &    (0.0118)   &    (0.0118)   &    (0.0115)   &    (0.0116)   \\
Phase 3 Clinical    &      0.0217   &      0.0214   &      0.0218   &      0.0216   &      0.0239   &      0.0236   &      0.0244   &      0.0241   \\
                    &    (0.0154)   &    (0.0154)   &    (0.0152)   &    (0.0152)   &    (0.0172)   &    (0.0171)   &    (0.0170)   &    (0.0169)   \\
Trial site in US=1  &      0.0090***&      0.0080***&      0.0076** &      0.0066*  &      0.0089***&      0.0077** &      0.0036   &      0.0026   \\
                    &    (0.0014)   &    (0.0015)   &    (0.0024)   &    (0.0023)   &    (0.0018)   &    (0.0020)   &    (0.0024)   &    (0.0025)   \\
Drug indication for neoplasm=1&      0.1360***&      0.1362***&      0.1341***&      0.1343***&      0.1489***&      0.1489***&      0.1421***&      0.1422***\\
                    &    (0.0140)   &    (0.0140)   &    (0.0112)   &    (0.0112)   &    (0.0176)   &    (0.0176)   &    (0.0125)   &    (0.0125)   \\
NIH funding         &      0.0094   &      0.0111   &      0.0089   &      0.0107   &      0.0098   &      0.0115   &      0.0075   &      0.0092   \\
                    &    (0.0058)   &    (0.0054)   &    (0.0056)   &    (0.0052)   &    (0.0063)   &    (0.0056)   &    (0.0052)   &    (0.0047)   \\
Biomarker type: genomic=1&      0.2192   &      0.2192   &      0.2191   &      0.2191   &      0.2162   &      0.2163   &      0.2157   &      0.2158   \\
                    &    (0.1088)   &    (0.1088)   &    (0.1090)   &    (0.1089)   &    (0.1113)   &    (0.1113)   &    (0.1116)   &    (0.1115)   \\
Public firm (lower bound)&      0.0137*  &               &      0.0137*  &               &      0.0162*  &               &      0.0161*  &               \\
                    &    (0.0053)   &               &    (0.0053)   &               &    (0.0070)   &               &    (0.0071)   &               \\
Public firm (upper bound)&               &      0.0153*  &               &      0.0153*  &               &      0.0171*  &               &      0.0169*  \\
                    &               &    (0.0056)   &               &    (0.0056)   &               &    (0.0072)   &               &    (0.0072)   \\
Trial site in US=1 $\times$ Drug indication for neoplasm=1&               &               &      0.0041   &      0.0042   &               &               &      0.0158
>    &      0.0157   \\
                    &               &               &    (0.0070)   &    (0.0070)   &               &               &    (0.0123)   &    (0.0124)   \\
Constant            &     -6.9518*  &     -6.9811*  &     -6.9607*  &     -6.9902*  &     -8.9285   &     -9.0424   &     -8.9047   &     -9.0177   \\
                    &    (2.7631)   &    (2.7080)   &    (2.7523)   &    (2.6972)   &    (4.6927)   &    (4.6770)   &    (4.7036)   &    (4.6890)   \\
N                   &      107430   &      107430   &      107430   &      107430   &       91371   &       91371   &       91371   &       91371   \\
r2                  &       0.255   &       0.255   &       0.255   &       0.255   &       0.262   &       0.263   &       0.263   &       0.263   \\
* p<0.05, ** p<0.01, *** p<0.001

. 
. * ------------------------------*
. * Duration regressions (Table 8)
. * ------------------------------*
. duration_regs, end_dates("actual") quietly
(7,269 observations deleted)
actual
(65,275 observations deleted)
(0 real changes made)

                    &       reg2a   &       reg2b   &       reg2c   &       reg2d   &       reg2e   &       reg2f   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year=2000&       0.000   &       0.000   &       0.000   &       0.000   &       0.000   &       0.000   \\
                    &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   \\
Trial start year=2001&      -1.770   &      -1.567   &      -1.391   &       2.606   &       3.016   &       3.113   \\
                    &     (1.594)   &     (1.589)   &     (1.865)   &     (2.421)   &     (2.419)   &     (2.415)   \\
Trial start year=2002&      -7.595***&      -7.075***&      -8.197***&      -2.530   &      -2.411   &      -2.172   \\
                    &     (1.458)   &     (1.454)   &     (1.719)   &     (2.323)   &     (2.295)   &     (2.292)   \\
Trial start year=2003&      -8.622***&      -8.002***&      -8.535***&      -5.010*  &      -4.433*  &      -4.032   \\
                    &     (1.404)   &     (1.401)   &     (1.666)   &     (2.253)   &     (2.241)   &     (2.239)   \\
Trial start year=2004&     -11.718***&     -11.138***&     -11.112***&      -6.748** &      -5.484*  &      -5.062*  \\
                    &     (1.340)   &     (1.338)   &     (1.581)   &     (2.143)   &     (2.131)   &     (2.130)   \\
Trial start year=2005&     -14.680***&     -13.914***&     -14.677***&     -10.661***&      -9.643***&      -9.086***\\
                    &     (1.309)   &     (1.308)   &     (1.531)   &     (2.054)   &     (2.043)   &     (2.047)   \\
Trial start year=2006&     -16.184***&     -15.450***&     -15.557***&     -10.468***&      -9.066***&      -8.451***\\
                    &     (1.289)   &     (1.288)   &     (1.506)   &     (1.998)   &     (1.995)   &     (1.998)   \\
Trial start year=2007&     -18.402***&     -17.587***&     -18.515***&     -14.901***&     -13.485***&     -12.813***\\
                    &     (1.277)   &     (1.276)   &     (1.486)   &     (1.972)   &     (1.955)   &     (1.961)   \\
Trial start year=2008&     -19.545***&     -18.781***&     -19.826***&     -16.726***&     -15.073***&     -14.361***\\
                    &     (1.270)   &     (1.269)   &     (1.476)   &     (1.970)   &     (1.962)   &     (1.965)   \\
Trial start year=2009&     -20.688***&     -19.959***&     -21.492***&     -18.528***&     -17.017***&     -16.185***\\
                    &     (1.263)   &     (1.262)   &     (1.467)   &     (1.955)   &     (1.930)   &     (1.937)   \\
Trial start year=2010&     -22.393***&     -21.762***&     -22.888***&     -24.081***&     -22.120***&     -21.450***\\
                    &     (1.261)   &     (1.259)   &     (1.465)   &     (1.942)   &     (1.926)   &     (1.930)   \\
Trial start year=2011&     -24.041***&     -23.410***&     -24.876***&     -27.675***&     -25.426***&     -24.673***\\
                    &     (1.254)   &     (1.253)   &     (1.452)   &     (1.940)   &     (1.906)   &     (1.911)   \\
Trial start year=2012&     -25.543***&     -24.979***&     -26.367***&     -31.887***&     -29.773***&     -29.147***\\
                    &     (1.253)   &     (1.252)   &     (1.455)   &     (1.954)   &     (1.928)   &     (1.930)   \\
Trial start year=2013&     -27.661***&     -27.108***&     -29.112***&     -37.395***&     -35.113***&     -34.305***\\
                    &     (1.251)   &     (1.249)   &     (1.448)   &     (1.923)   &     (1.903)   &     (1.907)   \\
Trial start year=2014&     -30.785***&     -30.141***&     -32.648***&     -43.301***&     -42.168***&     -41.456***\\
                    &     (1.248)   &     (1.247)   &     (1.440)   &     (1.910)   &     (1.895)   &     (1.897)   \\
Trial start year=2015&     -34.067***&     -33.353***&     -36.659***&     -50.134***&     -49.605***&     -48.747***\\
                    &     (1.249)   &     (1.248)   &     (1.444)   &     (1.972)   &     (1.924)   &     (1.930)   \\
Trial start year=2016&     -36.001***&     -35.295***&     -38.928***&     -55.694***&     -53.590***&     -52.983***\\
                    &     (1.258)   &     (1.258)   &     (1.462)   &     (2.413)   &     (2.330)   &     (2.334)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&       6.169***&       5.923***&       5.230***&       1.967** &       2.158***&       2.165***\\
                    &     (0.219)   &     (0.218)   &     (0.329)   &     (0.604)   &     (0.573)   &     (0.573)   \\
Phase 3 Clinical    &       9.307***&       9.427***&       6.855***&       8.777***&       9.792***&       9.772***\\
                    &     (0.252)   &     (0.250)   &     (0.394)   &     (1.288)   &     (1.261)   &     (1.255)   \\
Trial site in US    &       3.926***&       4.316***&               &               &               &               \\
                    &     (0.187)   &     (0.187)   &               &               &               &               \\
Drug indication for neoplasm&      19.054***&      18.895***&      17.922***&               &               &               \\
                    &     (0.264)   &     (0.263)   &     (0.367)   &               &               &               \\
Received NIH funding&      12.274***&      11.281***&      12.307***&       6.813***&       8.560***&       7.921***\\
                    &     (0.697)   &     (0.700)   &     (0.716)   &     (1.093)   &     (1.022)   &     (1.042)   \\
Public firm (lower bound)&      -6.044***&               &      -5.275***&               &      -3.925***&               \\
                    &     (0.184)   &               &     (0.277)   &               &     (0.577)   &               \\
Generous PPM        &       7.998***&       8.048***&       8.315***&               &       8.782***&       8.823***\\
                    &     (0.534)   &     (0.531)   &     (0.691)   &               &     (0.766)   &     (0.764)   \\
Public firm (upper bound)&               &      -7.239***&               &      -4.863***&               &      -4.750***\\
                    &               &     (0.189)   &               &     (0.617)   &               &     (0.589)   \\
Biomarker role (detailed): diagnosis&               &               &               &       2.644   &               &               \\
                    &               &               &               &     (1.491)   &               &               \\
Biomarker role (detailed): differential diagnosis&               &               &               &       3.974***&               &               \\
                    &               &               &               &     (1.188)   &               &               \\
Biomarker role (detailed): predicting drug resistance&               &               &               &      -2.046   &               &               \\
                    &               &               &               &     (1.287)   &               &               \\
Biomarker role (detailed): predicting treatment efficacy&               &               &               &       4.948***&               &               \\
                    &               &               &               &     (1.423)   &               &               \\
Biomarker role (detailed): predicting treatment toxicity&               &               &               &      -0.371   &               &               \\
                    &               &               &               &     (1.985)   &               &               \\
Biomarker role (detailed): screening&               &               &               &       1.008   &               &               \\
                    &               &               &               &     (1.583)   &               &               \\
Biomarker role (detailed): selection for therapy&               &               &               &       3.023*  &               &               \\
                    &               &               &               &     (1.215)   &               &               \\
Biomarker role (detailed): disease profiling&               &               &               &       1.043   &               &               \\
                    &               &               &               &     (1.119)   &               &               \\
Biomarker role (detailed): monitoring disease progression&               &               &               &      -1.320   &               &               \\
                    &               &               &               &     (1.492)   &               &               \\
Biomarker role (detailed): monitoring treatment efficacy&               &               &               &       1.371   &               &               \\
                    &               &               &               &     (1.199)   &               &               \\
Biomarker role (detailed): monitoring treatment toxicity&               &               &               &      -4.083   &               &               \\
                    &               &               &               &     (2.554)   &               &               \\
Biomarker role (detailed): not determined&               &               &               &       0.319   &               &               \\
                    &               &               &               &     (2.495)   &               &               \\
Biomarker role (detailed): prognosis&               &               &               &       0.448   &               &               \\
                    &               &               &               &     (1.376)   &               &               \\
Biomarker role (detailed): prognosis - risk stratification&               &               &               &       0.645   &               &               \\
                    &               &               &               &     (1.736)   &               &               \\
Biomarker role (detailed): risk factor&               &               &               &       0.112   &               &               \\
                    &               &               &               &     (1.156)   &               &               \\
Biomarker role (detailed): staging&               &               &               &      -4.436***&               &               \\
                    &               &               &               &     (1.324)   &               &               \\
Biomarker role (detailed): toxicity profiling&               &               &               &       7.726   &               &               \\
                    &               &               &               &    (10.268)   &               &               \\
Constant            &      38.927***&      39.440***&      44.358***&      60.026***&      60.587***&      60.857***\\
                    &     (1.251)   &     (1.250)   &     (1.439)   &     (1.778)   &     (1.785)   &     (1.786)   \\
N                   &       52929   &       52929   &       27861   &        8443   &        9315   &        9315   \\
r2                  &       0.326   &       0.332   &       0.294   &       0.199   &       0.183   &       0.184   \\
* p<0.05, ** p<0.01, *** p<0.001

. 
. 
. /*
> * ------------------------------*
> * Appendix reg table: (Table A11)
> * ------------------------------*
> ppm_regs, ppm(g_ppm) estimator(logit) margins quietly
> ppm_regs, ppm(r_ppm) estimator(logit) margins quietly
> */
. 
. 
. 
. log close
      name:  <unnamed>
       log:  /disk/homedirs/nber/bergerb/cortellis_projects/clinical_trials/reports/report_10-20-17/regs/regression_output_10-20-17.log
  log type:  text
 closed on:  29 Oct 2017, 16:48:33
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
